INTRODUCTION In 2009, the Biologics Price Competition and Innovation Act (BPCIA) paved the way for market entry of generic biologics by establishing a pathway for their regulatory approval. Proliferating with the advent of recombinant DNA technology, biologic drugs are derived from living organisms to create vaccines, blood products, allergenic products, monoclonal antibodies, cytokines, growth...
